If Novo Nordisk is to fulfil the potential of its anti-obesity drug Saxenda, it needs more doctors to have a new understanding of how obesity really works. And to prescribe. Again and again.
The race to find a pharmacological way to combat obesity is on — and in addition to financial pressures, it has proven devilishly difficult to make an obesity drug that is effective, safe and works at scale, across a population.
Getting doctors and medical bodies to classify obesity as a 'disease' would be a huge win for pharmaceutical companies. Here's how they're trying to do just that.